Aegera initiates Phase I diabetic neuropathy study

The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of AEG33773 using a randomized, double blind, placebo controlled, single ascending dose design in healthy male volunteers.

Michael Berendt, president and CEO of Aegera, said: “The Aegera team has successfully filed regulatory applications for two potential blockbuster compounds, AEG33773 and AEG40826, in the last three months while initiating multiple Phase II trials for our lead program AEG35156. Aegera now has four unique programs in clinical development and is poised to deliver significant clinical data over the next 12-18 months.”